Equity Profile

SNY

Sanofi

Health CarePharmaceuticals$104.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2012Pre-Market9:00 AM EDT

Company Snapshot

Sanofi (SNY) is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $104 billion, it plays a crucial role in addressing health challenges worldwide, particularly in areas like diabetes and rare diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Sanofi is managing its costs and revenues.

Expected to be above $2.45

Revenue Growth

Revenue growth is essential to gauge the company's market performance and demand for its products.

Expected to show positive growth year-over-year

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SNY Q2-2012 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+120.71%

Avg Stock Reaction

+1.51%

Last Quarter Recap

In the last quarter, Sanofi reported an impressive EPS of $2.45, exceeding expectations significantly. The stock reacted positively, gaining 2.28% the following day.

Management Promises & Guidance

Focus on expanding its diabetes and rare disease portfolios.
Commitment to enhancing research and development efforts.
Plans to increase market penetration in emerging markets.

Expectations

Wall Street Expectations

Overall, analysts are optimistic about Sanofi's upcoming earnings, expecting continued strong performance based on historical trends.

Bull Case

If Sanofi beats EPS expectations again, it could reinforce investor confidence and drive stock prices higher, potentially reflecting a strong demand for its products.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and market competitiveness, leading to a negative stock reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be above $2.45

EPS is a key indicator of profitability and will show how well Sanofi is managing its costs and revenues.

Revenue Growth

Expected to show positive growth year-over-year

Revenue growth is essential to gauge the company's market performance and demand for its products.

Market Share in Key Therapeutic Areas

Expected to maintain or grow market share

Understanding market share will indicate Sanofi's competitive position in the pharmaceutical industry.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the exact EPS figure reported this quarter?

Given Sanofi's history of beating EPS estimates, this figure will be crucial in determining market sentiment and stock movement.

How is Sanofi performing in its key therapeutic areas compared to competitors?

Market share dynamics will influence investor confidence and expectations for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Sanofi's ability to leverage its strong pipeline in emerging markets, which could lead to higher-than-expected revenue growth.

Supporting Evidence

Sanofi's recent focus on expanding its diabetes and rare disease portfolios suggests a strategic advantage.

Historical EPS surprises indicate a pattern of exceeding expectations, which could repeat this quarter.

Options pricing suggests a lower expected move, indicating that the market may not be fully pricing in potential upside.

Key Risk

If Sanofi's revenue growth exceeds expectations significantly, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around whether Sanofi can maintain its strong earnings performance amid competitive pressures.

Bull Confirmed If

An EPS of $2.50 or higher would confirm strong earnings momentum and likely lead to a bullish market reaction.

Bear Confirmed If

An EPS below $2.40 could signal potential issues in profitability and growth, leading to a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±1.28%

Historical Avg

±3.1%

Pricing cheap

The options market is pricing a modest move, suggesting that investors are anticipating a stable earnings report without significant surprises.

Options are pricing ±1.3% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.3%

30d HV

25.3%

Calls (55K)P/C Ratio: 0.34Puts (44K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sanofi beats expectations, history suggests a potential stock increase of around 1.51%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting cautious optimism without strong conviction.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.51% or more.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key therapeutic areas, especially diabetes and rare diseases.
2Any commentary on market share changes in competitive segments.
3Insights into R&D progress and upcoming product launches.
4Management's outlook on emerging markets and growth strategies.
5Details on cost management and operational efficiencies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Sanofi is managing its costs and revenues.

Expected to be above $2.45

Revenue Growth

Revenue growth is essential to gauge the company's market performance and demand for its products.

Expected to show positive growth year-over-year

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SNY Q2-2012 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+120.71%

Avg Stock Reaction

+1.51%

Last Quarter Recap

In the last quarter, Sanofi reported an impressive EPS of $2.45, exceeding expectations significantly. The stock reacted positively, gaining 2.28% the following day.

Management Promises & Guidance

Focus on expanding its diabetes and rare disease portfolios.
Commitment to enhancing research and development efforts.
Plans to increase market penetration in emerging markets.

Expectations

Wall Street Expectations

Overall, analysts are optimistic about Sanofi's upcoming earnings, expecting continued strong performance based on historical trends.

Bull Case

If Sanofi beats EPS expectations again, it could reinforce investor confidence and drive stock prices higher, potentially reflecting a strong demand for its products.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and market competitiveness, leading to a negative stock reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be above $2.45

EPS is a key indicator of profitability and will show how well Sanofi is managing its costs and revenues.

Revenue Growth

Expected to show positive growth year-over-year

Revenue growth is essential to gauge the company's market performance and demand for its products.

Market Share in Key Therapeutic Areas

Expected to maintain or grow market share

Understanding market share will indicate Sanofi's competitive position in the pharmaceutical industry.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the exact EPS figure reported this quarter?

Given Sanofi's history of beating EPS estimates, this figure will be crucial in determining market sentiment and stock movement.

How is Sanofi performing in its key therapeutic areas compared to competitors?

Market share dynamics will influence investor confidence and expectations for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Sanofi's ability to leverage its strong pipeline in emerging markets, which could lead to higher-than-expected revenue growth.

Supporting Evidence

Sanofi's recent focus on expanding its diabetes and rare disease portfolios suggests a strategic advantage.

Historical EPS surprises indicate a pattern of exceeding expectations, which could repeat this quarter.

Options pricing suggests a lower expected move, indicating that the market may not be fully pricing in potential upside.

Key Risk

If Sanofi's revenue growth exceeds expectations significantly, it could challenge the current consensus outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around whether Sanofi can maintain its strong earnings performance amid competitive pressures.

Bull Confirmed If

An EPS of $2.50 or higher would confirm strong earnings momentum and likely lead to a bullish market reaction.

Bear Confirmed If

An EPS below $2.40 could signal potential issues in profitability and growth, leading to a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±1.28%

Historical Avg

±3.1%

Pricing cheap

The options market is pricing a modest move, suggesting that investors are anticipating a stable earnings report without significant surprises.

Options are pricing ±1.3% while SNY has averaged ±3.1% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.3%

30d HV

25.3%

Calls (55K)P/C Ratio: 0.34Puts (44K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sanofi beats expectations, history suggests a potential stock increase of around 1.51%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting cautious optimism without strong conviction.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 1.51% or more.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of key therapeutic areas, especially diabetes and rare diseases.
2Any commentary on market share changes in competitive segments.
3Insights into R&D progress and upcoming product launches.
4Management's outlook on emerging markets and growth strategies.
5Details on cost management and operational efficiencies.